Development of Novel ADC-Resistant Models

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance.

At the 2025 Festival of Biologics Conference in San Diego, WuXi Biology presented a poster showcasing the development of various ADC-resistant cell lines (and subsequent in vivo models) through processes such as drug-induced resistance or efflux pump overexpression.  The authors describe how the resistant properties of these models have been validated both in vitro and in vivo. These drug resistant models offer crucial tools that can assist in the discovery and optimization of next-generation ADCs.

Festival of Biologics_Developing Novel Resistant Models to Accelerate Next-Generation ADC Drug Discovery final

Download